Research and Development Investment: Pharming Group N.V. vs Xenon Pharmaceuticals Inc.

Biotech R&D: A Decade of Growth and Innovation

__timestampPharming Group N.V.Xenon Pharmaceuticals Inc.
Wednesday, January 1, 20141418235311768000
Thursday, January 1, 20151550302815152000
Friday, January 1, 20161618358519828000
Sunday, January 1, 20172238284925573000
Monday, January 1, 20183303820623634000
Tuesday, January 1, 20193177704038845000
Wednesday, January 1, 20204146413450523000
Friday, January 1, 20216717805375463000
Saturday, January 1, 202252531000105767000
Sunday, January 1, 202368914000167512000
Loading chart...

Unleashing the power of data

A Decade of Innovation: R&D Investments in Biotech

In the ever-evolving world of biotechnology, research and development (R&D) investments are the lifeblood of innovation. Over the past decade, Pharming Group N.V. and Xenon Pharmaceuticals Inc. have demonstrated a steadfast commitment to advancing medical science. From 2014 to 2023, Pharming Group N.V. increased its R&D spending by nearly 386%, while Xenon Pharmaceuticals Inc. saw an impressive 1,324% surge.

Key Insights

Pharming Group N.V. began with a modest investment in 2014, but by 2023, their R&D expenses had grown significantly, reflecting their dedication to pioneering treatments. Meanwhile, Xenon Pharmaceuticals Inc. has consistently outpaced its counterpart, with its R&D expenses peaking in 2023, showcasing a strategic focus on groundbreaking therapies. This trend underscores the critical role of R&D in driving biotech innovation and the potential for transformative healthcare solutions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025